![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Ivax Receives Final Approval for Cilostazol Tablets
Ivax Receives Final Approval for Cilostazol Tablets
The FDA has approved Ivax's abbreviated new drug application for cilostazol tablets, 100 mg. Cilostazol is the generic equivalent of Otsuka American Pharmaceutical's Pletal tablets.
Ivax said the product will be sold through its Ivax Pharmaceuticals subsidiary. Cilostazol tablets are used to treat intermittent claudication, pain in the legs that happens when walking and goes away with rest. U.S. sales of 100-mg cilostazol tablets were $154.2 million in 2004, according to IMS Health data.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct